Last reviewed · How we verify
Migraine with aura
Approved treatments
- Zavzpret · Pfizer
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist for acute migraine treatment. - Zavzpret · Pfizer
Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission.
Clinical guidelines
- FDA label — 1L
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. - FDA label — 1L
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. - FDA label — 1L
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. - FDA label — 1L
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Migraine with aura patent landscape — cliff calendar, originator estates, attackable patents
- Migraine with aura treatment landscape brief
- Migraine with aura treatment updates RSS
Frequently asked questions about Migraine with aura
What drugs treat Migraine with aura?
Tracked treatments include Zavzpret.
What is the treatment for Migraine with aura?
Standard treatment for Migraine with aura includes Zavzpret. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Migraine with aura?
FDA label publishes guidelines for Migraine with aura. 4 guideline references tracked.
Related
- Treatment landscape: Migraine with aura patent cliff · Migraine with aura CI report
- Treatment: Zavzpret · Pfizer
- Treatment: Zavzpret · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing